PF-Atlas › Clinical Trials › NCT03921060
Markers of Osteoporosis in Cystic Fibrosis
Denosumab · Phase 4
Registry ID
NCT03921060
Phase
Phase 4
Status
Recruiting
Drug / intervention
Denosumab
Sponsor
University of Texas Southwestern Medical Center
Start
2021-09-02
Enrollment
100
Locations
1
About this trial
Main Study Up to 100 subjects, both non-CF volunteers and Cystic Fibrosis (CF) patients, will participate in a single study visit that will include a DEXA scan, micro CT, and blood collection. Denosumab (Prolia) Sub study Approximately 10 adult subjects with CF who participated in the main study and have results indicating bone disease will receive treatment with Denosumab for up to 5 years. They will be asked to return for repeat DEXA scans, micro CT, blood collection, and documenting of any adverse events.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT03921060 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.